Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (37)

2024

  1. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology

2023

  1. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

  2. Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study

    Cancer Medicine, Vol. 12, Núm. 6, pp. 6615-6622

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  3. Venous Thromboembolism In Cancer Patients: “From Evidence to Care”

    Clinical and Applied Thrombosis/Hemostasis, Vol. 28

2021

  1. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture

    Nature Communications, Vol. 12, Núm. 1

  2. Do clinical trials meet current care needs? Views of digestive oncology specialists in galicia (spain) using the delphi method

    Healthcare (Switzerland), Vol. 9, Núm. 6

  3. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

  4. Electronic health records and patient registries in medical oncology departments in Spain

    Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108

  5. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers

    Clinical and Experimental Metastasis, Vol. 38, Núm. 2, pp. 239-251

  6. PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study

    Lung Cancer Management, Vol. 10, Núm. 4

  7. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

    Scientific Reports, Vol. 11, Núm. 1

  8. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

    ESMO open, Vol. 6, Núm. 2, pp. 100090

2020

  1. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359

  2. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. CTCs expression profiling for advanced breast cancer monitoring

    Cancers, Vol. 11, Núm. 12

  3. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258

  4. Is there any affordable and reliable score in local gastric cancer?

    Annals of Oncology, Vol. 30, pp. iv60